ArticleeLife2015
Bioengineered human myobundles mimic clinical responses of skeletal muscle to drugs.
Article in eLife, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 216 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
216 citing papers in PubMed.
- Stable isotope-derived measurements of protein synthesis detect amino acid-induced anabolism in skeletal muscle microtissues not captured by puromycin labelling.Experimental physiology · 2026Article
- Bridging Organ-on-a-Chip and Omics: A Multi-Dimensional Frontier in Biomedical Research.Biotechnology and bioengineering · 2026Review
- A Biomimetic 3D Human Skeletal Muscle Microtissue for Modeling Biological and Functional Hallmarks of Aging.Small science · 2026Article
- Toward an Integrated Strategy for Volumetric Muscle Loss Regeneration.Journal of clinical medicine · 2026Review
- Duchenne muscular dystrophy: from gene to gene-ius therapies.Skeletal muscle · 2026Review
- RYR1Journal of translational medicine · 2026Article
- Three-dimensional models of skeletal muscle under tension: a systematic review and core outcome set.NPJ Regenerative medicine · 2026Article
- A 3D skeletal muscle system for disease modelling and secretome profiling of Duchenne muscular dystrophy.Skeletal muscle · 2026Article
- Fast-swimming biohybrid OstraBot with self-trained high-strength muscles.Nature communications · 2026Article
- MicroAge mission: experimental design and hardware for a bespoke culture system supporting tissue-engineered skeletal muscle.NPJ microgravity · 2026Article
- In vitro vascularization improves in vivo functionality of human engineered cardiac tissues.Acta biomaterialia · 2026Article
- Bioengineered Constructs as a Tissue Engineering-Based Therapy for Volumetric Muscle Loss.Tissue engineering. Part B, Reviews · 2026Review
- Fibrillar Bundles as Fibrous Filler Materials for Attaining Cell Anisotropy in Bioprinting.Advanced healthcare materials · 2026Article
- Disease exacerbation in human DMD MYOrganoids enables gene therapy evaluation and unveils persistence of fibrotic activity.NPJ Regenerative medicine · 2026Article
- Bioinspired hydrogel-based regenerative engineering strategies for the structural and functional regeneration of skeletal muscles following volumetric muscle loss.Regenerative biomaterials · 2026Review
- Crossbow Bioreactors for Studying the Effects of Time-Varying Mechanical Preload and Afterload on Engineered Cardiac Tissues.Advanced functional materials · 2025Article
- Biofabrication of a 3D human skeletal muscle microenvironment to study the early steps of fibrosis.Materials today. Bio · 2025Article
- Shaping 3D minimal model tissues with mechanical constraints to orchestrate muscle differentiation.Communications biology · 2025Article
- Complement-independent pathogenic influences of anti-HMGCR + and anti-SRP + immune-mediated necrotizing myopathy autoantibodies on engineered muscle function.Skeletal muscle · 2025Article
- Optical mapping of the interface between iPSC-derived grafts and swine myocardium suggests potential arrhythmia mechanisms.NPJ Regenerative medicine · 2025Article
156 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
Existing in vitro models of human skeletal muscle cannot recapitulate the organization and function of native muscle, limiting their use in physiological and pharmacological studies. Here, we demonstrate engineering of electrically and chemically responsive, contractile human muscle tissues ('myobundles') using primary myogenic cells. These biomimetic constructs exhibit aligned architecture, multinucleated and striated myofibers, and a Pax7(+) cell pool. They contract spontaneously and respond to electrical stimuli with twitch and tetanic contractions. Positive correlation between contractile force and GCaMP6-reported calcium responses enables non-invasive tracking of myobundle function and drug response. During culture, myobundles maintain functional acetylcholine receptors and structurally and functionally mature, evidenced by increased myofiber diameter and improved calcium handling and contractile strength. In response to diversely acting drugs, myobundles undergo dose-dependent hypertrophy or toxic myopathy similar to clinical outcomes. Human myobundles provide an enabling platform for predictive drug and toxicology screening and development of novel therapeutics for muscle-related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.